| Literature DB >> 12823293 |
H L Cooper1, E Healy, J M Theaker, P S Friedmann.
Abstract
We describe a 54-year-old man with resistant pemphigus vulgaris. Standard therapies had afforded inadequate control and have been associated with considerable side-effects. The anti-CD20 monoclonal antibody, Rituximab (MabThera, Roche), was trialled with significant benefit. We discuss its potential mechanism of action.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12823293 DOI： 10.1046/j.1365-2230.2003.01283.x
Source DB: PubMed Journal: Clin Exp Dermatol ISSN： 0307-6938 Impact factor: 3.470